Get the Stockscreener App
23.42
0.30%
-0.07
After Hours:
23.79
0.37
+1.58%
Arcutis Biotherapeutics Inc stock is traded at $23.42, with a volume of 850.23K.
It is down -0.30% in the last 24 hours and down -0.89% over the past month.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
See More
Previous Close:
$23.49
Open:
$23.72
24h Volume:
850.23K
Relative Volume:
0.68
Market Cap:
$2.93B
Revenue:
$376.07M
Net Income/Loss:
$-16.14M
P/E Ratio:
-167.41
EPS:
-0.1399
Net Cash Flow:
$-16.31M
1W Performance:
+0.56%
1M Performance:
-0.89%
6M Performance:
-3.94%
1Y Performance:
+51.98%
1-Day Range:
$23.15
$24.03
1-Week Range:
$22.13
$24.03
52-Week Range:
$12.42
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
23.42 | 2.94B | 376.07M | -16.14M | -16.31M | -0.1399 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis director Howard Welgus sells $164,219 in company stock - Investing.com
Arcutis Biotherapeutics (ARQT) director sells 7,144 shares under 10b5-1 plan - Stock Titan
Director sale: Arcutis Biotherapeutics (NASDAQ: ARQT) plans to sell 684 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) files to sell 1,341 vested shares via Merrill Lynch - Stock Titan
3,172-Share Form 144 Filed by Arcutis Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) reports vesting and insider sales in Form 144 - Stock Titan
UBS Group AG Boosts Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Kornitzer Capital Management Inc. KS Takes Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Howard Welgus sells 30,000 ARQT shares (NASDAQ: ARQT) across three dates - Stock Titan
Will Arcutis Biotherapeutics, Inc. (ARQT) report negative earnings next week? What you should know - MSN
Jennison Associates LLC Has $196.25 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Expected to Announce Earnings on Wednesday - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Buys 147,586 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Calamos Advisors LLC Takes $1.57 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis submits application to expand Zoryve use to infants - Investing.com UK
Arcutis Biotherapeutics (ARQT) Expands Zoryve Cream Application for Infants - GuruFocus
Arcutis submits sNDA for roflumilast cream 0.05% in atopic dermatitis for infants down to 3 months - Contemporary Pediatrics
Arcutis submits application to expand Zoryve use to infants By Investing.com - Investing.com South Africa
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months - The Manila Times
FDA filing targets eczema treatment for babies as young as 3 months - Stock Titan
ARQT Stock Price, Quote & Chart | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
Q4 2025 Arcutis Biotherapeutics Inc Earnings Call Transcript - GuruFocus
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves - Yahoo Finance
How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target - Yahoo Finance
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN) - The Globe and Mail
ARQT (Arcutis Biotherapeutics Inc.) tops Q4 2025 EPS estimates on 91 percent year over year revenue growth, shares slip 2.03 percent.Crowd Risk Alerts - Xã Thanh Hà
Is Arcutis (ARQT) stock building trend strength (Investor Interest) 2026-04-22Crowd Sentiment Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines - The Manila Times
AAD backs steroid-free ZORYVE for children with eczema - Stock Titan
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
[ARS] Arcutis Biotherapeutics, Inc. SEC Filing - Stock Titan
Arcutis Biotherapeutics (ARQT) 2026 proxy details votes on board, pay and auditor - Stock Titan
Is Arcutis (ARQT) stock losing support (Slight Loss) 2026-04-20Collaborative Trading Signals - Cổng thông tin điện tử Tỉnh Sơn La
Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants - Insider Monkey
5 Overlooked Growth Stocks to Buy Now - Insider Monkey
Phocas Financial Corp. Trims Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - The Manila Times
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis to give business update with Q1 results after market close May 6 - Stock Titan
Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70 - MSN
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive - Yahoo Finance
Tudor Investment Corp ET AL Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate - ChartMill
(ARQT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
AMI Asset Management Corp Sells 46,829 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):